The common interests of the Neuro-oncology Program are primary malignant brain tumors of adults and children. The scientific goals are:
Aim 1 : to conduct epidemiological and molecular epidemiological studies to invesfigate efiology and to identify populafions at greater and lesser risk for development of malignant brain tumors in adults and children;
Aim 2 : to determine molecular mechanisms of transformafion, altered growth control, and invasion of malignant brain tumors of adults and children;
Aim 3 : to identify new drugs active against primary brain tumors of adults and children, to determine mechanisms of drug resistance in primary brain tumors, and to institute methods to overcome drug resistance;
Aim 4 : to develop monoclonal antibodies and recombinant DNA anfibody fragments reactive with molecular targets, primary brain tumors, and to develop immunoconjugates for brain tumor treatment;
Aim 5 : to develop new radiolabeling technology for peptides and monoclonal antibodies and their fragments that will facilitate the invesfigafion of promising radionuclides, including the a-emitter ^""""""""Astafine and the p-emitter ^''''Lutetium, in targeted radiotherapy clinical trial for brain tumor patients;
Aim 6 : to develop cell-mediated immunotherapy and dendritic-based vaccine trials for brain tumors;
Aim 7 : to develop oncolytic poliovirus with no neurovirulence, but retention of oncolytic capacity for gliomas, into a reagent that can be used for therapy of malignant gliomas and neoplastic meningifis from breast cancer;
Aim 8 : to develop imaging capabilifies with Positron Emission Tomography (PET) for improved brain tumor diagnosis, monitoring of therapeutic response, and determinafion of pafient-specific radiafion dosimetry in radiolabeled anfibody, chemotherapy and small molecular inhibitor clinical trials in brain tumor patients;
Aim 9 : to design and execute Phase I, Phase 11, and Phase 111 clinical trials in primary and metastafic brain tumors in adults and children, based on laboratory discoveries within the Program, and to execute clinical trials for improvement of quality of life in brain tumor pafients. The Program includes 26 members from 12 basic and clinical departments within Duke University. Total funding for program members is $18,693,484, of which $10,458,928 is from peer- reviewed sources. A cancer focus is illustrated by $5,092,026 or 48.7% of funding from the NCI, the American Cancer Society or the Department of Defense. From 2004-2008, program members published 612 papers in peer-reviewed journals cited in PubMed. Of these publications, 20% are the result of intra-programmatic collaborafions and 27% due to inter-programmafic collaborafions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014236-40
Application #
8601816
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-01-01
Budget End
2014-12-31
Support Year
40
Fiscal Year
2014
Total Cost
$24,713
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Wu, Mengxi; Huang, Po-Hsun; Zhang, Rui et al. (2018) Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation. Small 14:e1801131
Vlahovic, Gordana; Meadows, Kellen L; Hatch, Ace J et al. (2018) A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer. Oncologist 23:782-790
Xu, Yinghui; Liu, Hongliang; Liu, Shun et al. (2018) Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer. Int J Cancer 143:2400-2408
Feng, Yun; Wang, Yanru; Liu, Hongliang et al. (2018) Novel genetic variants in the P38MAPK pathway gene ZAK and susceptibility to lung cancer. Mol Carcinog 57:216-224
Naqvi, Ibtehaj; Gunaratne, Ruwan; McDade, Jessica E et al. (2018) Polymer-Mediated Inhibition of Pro-invasive Nucleic Acid DAMPs and Microvesicles Limits Pancreatic Cancer Metastasis. Mol Ther 26:1020-1031
Wen, Juyi; Liu, Hongliang; Wang, Lili et al. (2018) Potentially Functional Variants of ATG16L2 Predict Radiation Pneumonitis and Outcomes in Patients with Non-Small Cell Lung Cancer after Definitive Radiotherapy. J Thorac Oncol 13:660-675
Li, Bo; Wang, Yanru; Xu, Yinghui et al. (2018) Genetic variants in RORA and DNMT1 associated with cutaneous melanoma survival. Int J Cancer 142:2303-2312
Gearhart-Serna, Larisa M; Jayasundara, Nishad; Tacam Jr, Moises et al. (2018) Assessing Cancer Risk Associated with Aquatic Polycyclic Aromatic Hydrocarbon Pollution Reveals Dietary Routes of Exposure and Vulnerable Populations. J Environ Public Health 2018:5610462
Bakthavatsalam, Subha; Sleeper, Mark L; Dharani, Azim et al. (2018) Leveraging ?-Glutamyl Transferase To Direct Cytotoxicity of Copper Dithiocarbamates against Prostate Cancer Cells. Angew Chem Int Ed Engl 57:12780-12784
Dai, Ziwei; Mentch, Samantha J; Gao, Xia et al. (2018) Methionine metabolism influences genomic architecture and gene expression through H3K4me3 peak width. Nat Commun 9:1955

Showing the most recent 10 out of 513 publications